Company intelligence / Profile preview
NovAccess Global
Chagrin Falls, Ohio, United Statesnovaccessglobal.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Preclinical
01
Overview
NovAccess Global is developing TLR-AD1, an immunotherapy candidate currently in the IND filing stage. Pre-clinical tests have shown that their mix of TLR adjuvants combined with patient tumor antigens stimulates an increased immune response compared to prior generations of the therapy[8].
- Therapeutic areas
- Oncology
- Modalities
- ImmunotherapyTherapeutic vaccinesDendritic cell vaccines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CKN Ventures
Beyond the preview
Go deeper on NovAccess Global.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovAccess Global.